Will AbbVie back off Humira advertising now that it’s announced it will buy Allergan? Maybe. But for now, the Illinois drugmaker is showing no signs of slowing its long-running robust TV ad push for ...

The fall magazines are always fat with ads, and the latest issues of People were no exception. I was happy to spot many DTC ads in one very hefty issue, two of which really stood out—one for Pfizer’s ...

More than one-fourth of all top-10 pharma TV spending in July came from one brand—AbbVie's Humira. The immunology blockbuster brand dropped $42.5 million on TV ads, well ahead of Gilead Sciences’ ...

WASHINGTON (Reuters) - An advertisement for Abbott Laboratories' Humira minimizes the arthritis drug's risks while suggesting it can treat a wider range of patients than it is approved to treat, the U ...

The second in a pair of complementary spots for AbbVie’s immunology drug Humira recently hit airwaves, and while it shed some light on the mysterious ad that preceded it, the sequence has elicited a ...

Image above from a recent Humira ad. The Humira wars have begun, as the first branded biosimilar to break Abbvie’s 20-year exclusivity on the top-selling anti-inflammatory drug has launched, cutting ...

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor. Starting July 1, alternatives to the ...

July 27 (Reuters) - AbbVie (ABBV.N), opens new tab on Thursday trimmed its 2023 view for declining sales of its flagship arthritis drug Humira despite new competition, as favorable positions on ...

Humira (adalimumab) is a prescription drug that’s used to treat certain types of arthritis and other inflammation-related diseases. It comes as a liquid solution for injection under your skin. Humira ...